Introduction

IL-2 is primarily produced by CD4
þ T cells upon activation. It is a growth and differentiation factor that plays an important role in regulating immune homeostasis. In humans, dysregulation of IL-2 production has been associated with a variety of immunological disorders including autoimmune disease. 1, 2 Mice homozygous for a targeted disruption of IL2, IL2Ra or IL2Rb die early in life of acute lymphoproliferation and autoimmunity, [3] [4] [5] and normal mice treated with neutralizing anti-IL-2 antibody develop organ-specific autoimmune diseases 6 similar to those observed in adult mice induced by day 3 neonatal thymectomy (D3Tx). 7 In contrast, mice overexpressing IL-2 exhibit exacerbated inflammatory responses but not autoimmunity. [8] [9] [10] The autoimmune phenomena observed in IL2/IL2R knockout mice and in D3Tx mice have been attributed, in part, to defects in the development and homeostasis of CD4 þ CD25 þ Foxp3 þ T regulatory cells. 6, [11] [12] [13] [14] [15] IL2 and IL2Ra have been associated with susceptibility to several human autoimmune diseases including multiple sclerosis, celiac disease, systemic sclerosis and type I diabetes. [16] [17] [18] [19] [20] In mice, a S-6-P sequence polymorphism in IL-2 21 has been reported to be associated with susceptibility to type I diabetes 22 and experimental autoimmune encephalomyelitis (EAE). 23 However, this association with type I diabetes susceptibility was not confirmed in a subsequent study. 24 In humans, a À330 single-nucleotide polymorphism (SNP) in the IL2 promoter affecting expression levels has been associated with increased susceptibility to multiple sclerosis, and a À384 SNP has been associated with susceptibility to systemic sclerosis. 16, 19 In mice, no specific SNPs in the IL2 promoter have yet been related to autoimmune disease susceptibility. However, it was recently reported that Idd3 alleles correlate with differential expression of IL-2, which in turn may affect the function and recruitment of T regulatory cells. 24 In this regard, we previously identified IL2 as a candidate for Aod2, a quantitative trait locus (QTL) controlling susceptibility to D3Tx-induced autoimmune ovarian dysgenesis (AOD). 25, 26 Importantly, D3Tx results in a loss of peripheral tolerance mediated by T regulatory cells. 11, 15 On the basis of comparative linkage analysis, we showed that Aod2 colocalized with Idd3 and Eae3, and hypothesized that IL2 polymorphism may represent an additional example of a shared autoimmune diseasesusceptibility gene similar to Bphs. [27] [28] [29] [30] Notably, the region encompassing IL2 (KIAA1109/Tenr/IL2/IL21) has recently been reported to harbor a shared autoimmune disease-susceptibility locus for celiac disease, type I diabetes and rheumatoid arthritis. 31 Here, we report the identification of SNPs within a region upstream of the minimal murine IL2 promoter, which results in differential IL-2 expression by CD4 þ T cells. We demonstrate that these positions are key for binding of specific transcription factors such as AP-1 and for transcriptional regulation of IL2 expression. Moreover, we show that these same SNPs segregate with Idd3 and Eae3, suggesting that they are not only candidates for Aod2, but that they are also candidates for a shared autoimmune disease-susceptibility locus underlying Idd3 and Eae3.
Results and discussion IL-2 expression by A/J and B6/J CD4 þ T cells Autoimmune ovarian dysgenesis can be induced by D3Tx of genetically susceptible A/J mice but not B6/J mice. 7, 25, 26, 32 We previously showed that AOD susceptibility is controlled by multiple QTL (Aod1a, Aod1b, Aod2, Aod3, Aod4, Aod5 and H2) 26, 32 and that Aod2 was linked to IL2, Idd3 and Eae3 on mouse chromosome 3. Recently, it was reported that Idd3 alleles correlate with differential expression of IL-2. 24 To investigate whether differential expression of IL-2 segregates with Aod2, we stimulated A/J and B6/J CD4 þ T cells with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) and quantified IL-2 production by enzyme-linked immunosorbent assay (ELISA). Compared to B6/J CD4 þ T cells, CD4 þ T cells from A/J mice produced significantly less IL-2 ( Figure 1a ). No differences were detected in IFNg (Figure 1b ) or IL-3 ( Figure 1c ) production, suggesting that the increase of IL-2 is specific and not due to a general hyperresponsiveness of the cells. To determine whether the levels of IL-2 reflected differences in gene expression, we examined IL2 mRNA levels in activated CD4 þ T cells by ribonuclease protection assay. IL2 mRNA levels were significantly greater in B6/J CD4 þ T cells compared with A/J CD4 þ T cells (Figure 1d ). These results show that IL2 is differentially expressed in B6/J and A/J CD4 þ T cells and that differential expression segregates with susceptibility and resistance to AOD.
IL-2 expression by SJL/J and B10.S CD4
þ T cells Eae3, an autoimmune susceptibility locus in EAE, colocalizes with Aod2. 23, 25, 26 Given that differential expression of IL-2 segregates with Aod2 (Figure 1 ), we investigated if expression of IL-2 also segregates with Eae3. Therefore, we compared IL-2 production by EAEresistant B10.S CD4 þ T with EAE-susceptible CD4 þ T cells following in vitro stimulation with anti-CD3 and anti-CD28 mAbs. B10.S CD4 þ T cells produced significantly more IL-2 than SJL/J CD4 þ T cells (Figure 2a) . Similarly, IL2 mRNA levels were greater in B10.S CD4 þ T cells compared with SJL/J CD4 þ T cells (Figure 2b ). Taken together, these results indicate that differential expression of IL2 also segregates with Eae3.
Single-nucleotide polymorphisms within the À1.2 kb to À300 bp region of the IL-2 locus control differential IL-2 expression To address whether IL2 expression is due to genetic variation in the IL2 promoter, we cloned and sequenced þ T cells from SJL/J or B10.S mice were stimulated with anti-CD3 and anti-CD28 mAbs for 24 h. mRNA levels of IL-2, IFNg and the housekeeping gene L32 are shown. No other cytokine mRNAs were detected. ELISA data represent the mean ± s.d. of three independent experiments; *Po0.05 as assessed using two-way analysis of variance followed by Bonferroni-corrected post hoc multiple comparisons. RPA data are representative of three independent experiments.
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R del Rio et al (À300 to þ 1 bp) were identified among the strains. However, nine previously unreported SNPs and two deletion mutations were identified upstream of the minimal promoter ( Figure 3a and Supplementary Figure  S1 ). Importantly, a single autoimmune disease-resistant high IL-2 producer haplotype was identified in B6/J and B10.S mice. In contrast, two autoimmune diseasesusceptible low IL-2 producer haplotypes were identified in A/J, SJL/J and NOD mice. The A/J-SJL/J haplotype was identical to the NOD haplotype with the exception of the G-A at À694. Seven of the polymorphisms were located in a region more proximal to the minimal promoter (À1.2 kb to -300 bp), whereas four were located in a more distal region (À2.8 to À1.2 kb). We hypothesized that any or all of these polymorphisms could potentially influence the efficacy of the minimal promoter to mediate transcription of IL2 in CD4 þ T cells. To examine the transcriptional activity of the B6/ J-B10.S and A/J-SJL/J IL2 promoters, we generated reporter constructs where the À2.8 kb to þ 1 bp region of the IL2 locus from B6/J and A/J mice were cloned upstream of the luciferase gene. These constructs were transfected into freshly isolated CD4 þ T cells by nucleofection. Cells were then activated with anti-CD3 and anti-CD28 mAbs and the luciferase activity quantified. The transcriptional activity of the A/J-SJL/J À2.8 kb haplotype was significantly reduced compared with the activity of the B6/J-B10.S À2.8 kb haplotype ( Figure 3b) . As a first approach to characterize the contribution of these SNPs to the differential activity of the IL2 promoter, we generated reporter constructs with truncated versions of the À2.8 kb haplotypes. Reporter constructs containing the minimal promoter (À300 to þ 1 bp) and the À1.2 kb to -300 bp region of the B6/J-B10.S and A/J-SJL/J haplotypes were transfected into freshly isolated CD4 þ T cells. Transcriptional activity upon activation was determined. Similar to the results obtained with the À2.8 kb to þ 1 bp haplotypes, transcription mediated by the À1.2 kb to þ 1 bp A/J-SJL/J haplotype was significantly reduced compared with the transcription activity of the B6/J-B10.S haplotype (Figure 3c ). We also transfected freshly isolated CD4 þ T cells with reporter constructs containing the À2.8 to À1.2 kb B6/J-B10.S and A/J-SJL/J haplotypes followed by the minimal promoter. Interestingly, no difference in transcriptional activity between the two distal haplotypes was observed Genetic control of IL-2 expression R del Rio et al (Figure 3c ). These results indicated that the SNPs present in the À1.2 kb to À300 bp region (proximal to the minimal promoter), and not the more distal region, regulate the enhanced transcriptional activity associated with the B6/J-B10.S IL2 promoter haplotype. To further demonstrate the role of the SNPs in the proximal region, we generated hybrid constructs containing either the A/J-SJL/J proximal region and B6/J-B10.S distal region (B6/J-A/J) or the A/J-SJL/J distal region and B6/J-B10.S proximal region (A/J-B6/J). The luciferase activity of the B6/J-A/J À2.8 kb IL2 hybrid construct was significantly reduced compared to the A/J-B6/J À2.8 kb IL2 hybrid construct (Figure 3d ), confirming that one or more SNPs located in the À1.2 kb to À300 bp region are responsible for the different transcriptional activity of the B6/J-B10.S and A/J-SJL/J IL2 promoter haplotypes.
To determine which of the SNPs within the À1.2 kb proximal region of the B6/J-B10.S IL2 promoter haplotype contribute to the enhanced transcriptional activity, we replaced each of the A/J-SJL/J alleles with B6/J-B10.S alleles and generated reporter constructs. Each construct was transfected into freshly isolated CD4 þ T cells that were stimulated with anti-CD3 and anti-CD28 mAb. Replacement of the A/J-SJL/J allele at À1010 with the B6/J-B10.S allele significantly increased transcriptional activity. Similar results were obtained when the A/J-SJL/J alleles at À962, À925/À926, À914 and À674 were replaced with B6/J-B10.S alleles, with the À674 SNP causing the major effect (Figure 3e ). In contrast, replacement of the À921 A/J-SJL/J allele with the B6/J-B10.S allele significantly reduced the transcriptional activity (Figure 3e) . Together, these results showed that the SNPs at À1010, À962, À925/À926, À914 and À674 within the proximal À1.2 kb region of the B6/J-B10.S and A/J-SJL/J IL2 promoter haplotypes control differential expression of IL-2 in CD4 þ T cells.
B6/J-B10.S À1010 SNP allele is essential for AP-1 binding
In an effort to understand how the À1.2 kb haplotypeassociated SNP alleles contribute to differential transcriptional activity, we analyzed the sequences for the presence of potential transcription factor binding sites using the TESS (http://www.cbil.upenn.edu/tess) and TFSEARCH software (http://www.cbrc.jp/ research/db/TFSEARCH.html). Putative AP-1-(À1015 to À1009), CRE-like-(À966 to À960) and MYC/MAX (À916 to À911)-binding sites were predicted (Supplementary Figure S1 ). In contrast, no significant similarities to known regulatory elements were found in the regions spanning the other polymorphisms. Electrophoretic mobility shift assays (EMSAs) using nuclear extracts from nonstimulated and stimulated B6/J CD4 þ T cells were carried out to determine whether the B6/J-B10.S SNP alleles influence the binding of specific nuclear factors to these potential cis-elements. þ T cells stimulated for 24 h were analyzed by EMSA using double-stranded oligonucleotide containing the À1010 SNP from B6/J-B10.S. Binding reactions were performed in the presence of indicated antibodies (Ab). Representative data from two or more independent experiments are shown.
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A/J-SJL/J-NOD probes (unpublished data). Similar results were obtained with an oligonucleotide containing the À962 SNP (Figure 4b and unpublished data). The B6/J-B10.S À925/À926, À921 and À914 SNP alleles were tested using a single oligonucleotide due to the proximity of the SNPs. A weak nuclear complex was detected with both the B6/J-B10.S and A/J-SJL/J-NOD oligonucleotides but again, only in nonstimulated cells (Figure 4c and unpublished data) . Some of these complexes present in nonstimulated cells may represent repressors of IL2 gene expression, since they are downregulated upon activation as has been reported for CREM. 1, 33, 34 The À1010 SNP mapped in a canonical AP-1-binding motif with the B6/J-B10.S allele resulting in a complete match with the consensus AP-1-binding sequence (TGAGTCA). In contrast, the A/J-SJL/J-NOD allele at À1010 alters a key position required for AP-1 binding (TGAGTTA). Therefore, EMSA analysis was performed to assess the ability of AP-1 proteins to bind the C and/or T alleles using B6/J-B10.S or A/J-SJL/J-NOD oligonucleotides that include the AP-1 site. A weak complex resembling a CREB-like complex was observed in nonstimulated cells (Figure 4d) . A strong complex resembling the AP-1 complex obtained with a consensus AP-1 oligonucleotide 35 was present when the B6/J-B10.S probe was used (Figure 4d) . Importantly, no AP-1 binding was detected with the A/J-SJL/J-NOD oligonucleotide (Figure 4d) . Furthermore, only a cold B6/ J-B10.S and non-cold A/J-SJL/J-NOD oligonucleotide could compete the binding of the AP-1 complex to the labeled B6/J-B10.S probe (Figure 4d ).
The AP-1 complex is composed of proteins belonging to the basic leucine zipper Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB, Fra-1 and Fra-2) families. 36 To address which member(s) of the Jun and Fos families are present in the complex bound to the B6/J-B10.S À1010 oligonucleotide, we carried out competition analysis using Abs against different family members. Anti-c-Fos or anti-Fra1 Abs diminished the nuclear DNA binding, indicating that both nuclear factors are present in the complex bound to the À1010 probe (Figure 4e) . Similarly, the presence of anti-c-Jun, anti-JunB or anti-JunD Abs also reduced the binding of the complex to the B6/ J-B10.S À1010 oligonucleotide, indicating that these Jun members were present in the complex (Figure 4f ). Complete abrogation of the DNA binding to the À1010 probe was observed when the three anti-Jun Abs were added (Figure 4f ). Control Abs specific for the p50 NFkB family member and Ets1 had no effect on the AP-1 complex bound to the À1010 oligonucleotide (Figure 4g ). Taken together, these findings indicated that the À1010 C-T SNP plays a critical role in AP-1 binding and suggest that AP-1-dependent transcription of IL2 contributes to differential expression of IL-2 in B6/J-B10.S and A/J-SJL/J-NOD CD4 þ T cells.
Conclusions
Previously, we identified IL2 as a candidate for a shared autoimmune disease-susceptibility locus underlying Aod2, Idd3 and Eae3. 25, 26 Recent studies showed that differential expression of IL2 by CD4 þ T cells segregates with Idd3. 24 However, the polymorphisms controlling IL2 expression were not characterized. We have now identified novel SNPs upstream of the minimal IL2 promoter that control differential expression of IL2 by CD4 þ T cells and segregate with Aod2, Idd3 and Eae3; as such, they are candidates for a shared autoimmune disease-susceptibility locus. Importantly, we provide evidence for the first time that differences in AP-1 binding to an element proximal to and outside of the minimal promoter contribute to these differences. We propose that polymorphisms that affect critical DNA regulatory elements and transcription of IL2 contribute to susceptibility and resistance to autoimmune disease by modifying the genesis, function and/or recruitment of T regulatory cells either at the level of the target organ or the draining lymph node. 15 
Materials and methods
Mice A/J, B10.S-H2 s /SgMcdJ (B10.S), C57BL/6J (B6/J), NOD/ ShiLtJ (NOD) and SJL/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained in the pathogen-free vivarium at the University of Vermont.
CD4
þ T-cell purification and activation CD4 þ T cells were isolated by negative selection as previously described. 37, 38 Cells were activated with platebound anti-CD3 (2C11) (5 mg ml À1 ) and soluble anti-CD28 mAb (1 mg ml À1 ) in 10% FBS-RPMI 1640 medium for different times, as indicated.
ELISA
Enzyme-linked immunosorbent assays were performed as previously described 37 using cytokine-specific capture and detection mAbs (BD Pharmingen, Franklin Lakes, NJ, USA) according to the recommended protocol (BD Pharmingen). Recombinant mouse IL-2, IFNg and IL-3 (R&D Systems, Minneapolis, MN, USA) were used as standards.
RNA analysis
Total RNA was extracted from cells using Ultraspec RNA Isolation Reagent (Biotecx Laboratories Inc., Houston, TX, USA) as recommended by the manufacturer. RNase protection assays with the mCK-1 RiboQuant multiprobe template set (BD Biosciences, Franklin Lakes, NJ, USA) were carried out using 3 mg of total RNA from stimulated CD4 þ T cells according to the manufacturer's instructions.
T-cell transfection B6/J CD4 þ T cells were electroporated with 5 mg of plasmid using an AMAXA electroporator and AMAXA nucleofector kit for primary murine T cells according to the manufacturer's instructions (Amaxa Biosystems, Cologne, Germany). After 7 h of transfection, the cells were stimulated as described above.
Plasmid constructs
The mouse IL2 promoter (À2.8 kb to À1 bp) (GeneBank accession X52618) was isolated by PCR from A/J, B10.S, B6/J, NOD and SJL/J genomic DNA and subcloned into the luciferase reporter vector pGL4. 10 [luc2] (Promega Corporation, Madison, WI, USA). The nucleotide identity Genetic control of IL-2 expression R del Rio et al was verified by sequencing both strands. Site-directed mutagenesis was performed using the QuikChanges II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). All derivatives of A/J À1.2 kb were sequenced to verify correct introduction of mutations and the absence of undesirable mutations.
Luciferase assay
Luciferase activity in the cell extracts was measured with the luciferase assay system (Promega Corporation). Relative light units were measured with a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA, USA).
EMSA Nuclear extracts were obtained as previously described. 39 Binding reactions were carried out using 2 mg nuclear extracts and In EMSA competition studies, nuclear extracts were incubated with 100-fold excess of unlabeled competitor. Anti-c-Fos, anti-Fra-1, anti-c-Jun, anti-JunB, anti-JunD, anti-p50 and anti-Ets1 antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were used in competition assays.
